Suscripción a Biblioteca: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Publicado 6 números por año

ISSN Imprimir: 1045-4403

ISSN En Línea: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Anti-Osteoactivin Antibody Inhibits Osteoblast Differentiation and Function In Vitro

Volumen 13, Edición 2-4, 2003, 12 pages
DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i24.180
Get accessGet access

SINOPSIS

Osteoactivin (OA) is a novel protein identified by mRNA differential display using bone from osteopetrotic versus normal rats. Bioinformatic analysis showed that OA cDNA has an open reading frame of 1716 bp encoding a protein of 572 aa, the first 21 aa constitute a signal peptide. OA sequence analysis also demonstrated 13 putative N-glycosylation sites suggestive of a heavily glycosylated protein. In this study, we localized OA protein in primary osteoblast culture by immunofluorescent staining and Western blot analysis. Primary osteoblast cultures pass through three stages: proliferation from day 1 to 7, matrix formation from day 7 to 14, and matrix mineralization from day 14 to 21. OA protein was detected at all stages examined, with maximal expression at 3 weeks when osteoblasts are terminally differentiated. Using the Chariot transfection reagent as a vehicle to deliver anti-OA antibody into the cells, we demonstrated that anti-OA antibody significantly inhibited osteoblast differentiation markers, including alkaline phosphatase activity, nodule formation, osteocalcin production, and calcium deposition, without affecting cell proliferation or viability. These data suggest that OA is an osteoblast-related protein that plays an important role in the regulation of osteoblast differentiation and function.

CITADO POR
  1. Ashraf Nomaan, Meyer Martha H, Frick Steven, Meyer Ralph A, Evidence for Overgrowth after Midfemoral Fracture via Increased RNA for Mitosis, Clinical Orthopaedics and Related Research, 454, 2007. Crossref

  2. Moffatt Pierre, Gaumond Marie-Helene, Salois Patrick, Sellin Karine, Bessette Marie-Claude, Godin Éric, de Oliveira Paulo Tambasco, Atkins Gerald J, Nanci Antonio, Thomas Gethin, Bril: A Novel Bone-Specific Modulator of Mineralization, Journal of Bone and Mineral Research, 23, 9, 2008. Crossref

  3. Abdelmagid Samir M., Barbe Mary F., Hadjiargyrou Michael, Owen Thomas A., Razmpour Roshanak, Rehman Saqib, Popoff Steven N., Safadi Fayez F., Temporal and spatial expression of osteoactivin during fracture repair, Journal of Cellular Biochemistry, 111, 2, 2010. Crossref

  4. Abdelmagid Samir M., Barbe Mary F., Arango-Hisijara Israel, Owen Thomas A., Popoff Steven N., Safadi Fayez F., Osteoactivin acts as downstream mediator of BMP-2 effects on osteoblast function, Journal of Cellular Physiology, 210, 1, 2007. Crossref

  5. Litvin Judith, Selim Abdul-Hafez, Montgomery Michael O., Lehmann Kiyoko, Rico Mario C., Devlin Hugh, Bednarik Daniel P., Safadi Fayez F., Expression and function of periostin-isoforms in bone, Journal of Cellular Biochemistry, 92, 5, 2004. Crossref

  6. Singh Maneet, Del Carpio-Cano Fabiola E., Monroy M. Alexandra, Popoff Steven N., Safadi Fayez F., Homeodomain transcription factors regulate BMP-2-induced osteoactivin transcription in osteoblasts, Journal of Cellular Physiology, 227, 1, 2012. Crossref

  7. Saxena Sunil K., Kaur Simarna, George Constantine, Rab4GTPase modulates CFTR function by impairing channel expression at plasma membrane, Biochemical and Biophysical Research Communications, 341, 1, 2006. Crossref

  8. Wang Minhua H., Frishman Laura J., Otteson Deborah C., Intracellular delivery of proteins into mouse Müller glia cells in vitro and in vivo using Pep-1 transfection reagent, Journal of Neuroscience Methods, 177, 2, 2009. Crossref

  9. Arnott J.A., Zhang X., Sanjay A., Owen T.A., Smock S.L., Rehman S., DeLong W.G., Safadi F.F., Popoff S.N., Molecular requirements for induction of CTGF expression by TGF-β1 in primary osteoblasts, Bone, 42, 5, 2008. Crossref

  10. Hong Dun, Chen Hai-Xiao, Ge Renshan, Li Ji-Cheng, Genetically Engineered Mesenchymal Stem Cells: The Ongoing Research for Bone Tissue Engineering, The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology, 293, 3, 2010. Crossref

  11. Sheng Matilda H.-C., Wergedal Jon E., Mohan Subburaman, Lau K.-H. William, Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity, FEBS Letters, 582, 10, 2008. Crossref

  12. Huang Jian‐Jun, Ma Wen‐Jie, Yokoyama Shigeru, Expression and immunolocalization of Gpnmb, a glioma‐associated glycoprotein, in normal and inflamed central nervous systems of adult rats, Brain and Behavior, 2, 2, 2012. Crossref

  13. Bateman J. P., Safadi F. F., Susin C., Wikesjö U. M. E., Exploratory study on the effect of osteoactivin on bone formation in the rat critical-size calvarial defect model, Journal of Periodontal Research, 47, 2, 2012. Crossref

  14. Wang Tao, Ge Yingbin, Xiao Min, Lopez-Coral Alfonso, Azuma Rikka, Somasundaram Rajasekharan, Zhang Gao, Wei Zhi, Xu Xiaowei, Rauscher Frank J., Herlyn Meenhard, Kaufman Russel E., Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature, Pigment Cell & Melanoma Research, 25, 4, 2012. Crossref

  15. Sondag Gregory R., Salihoglu Sibel, Lababidi Suzanne L., Crowder Douglas C., Moussa Fouad M., Abdelmagid Samir M., Safadi Fayez F., Osteoactivin Induces Transdifferentiation of C2C12 Myoblasts Into Osteoblasts, Journal of Cellular Physiology, 229, 7, 2014. Crossref

  16. Moussa Fouad M., Hisijara Israel Arango, Sondag Gregory R., Scott Ethan M., Frara Nagat, Abdelmagid Samir M., Safadi Fayez F., Osteoactivin Promotes Osteoblast Adhesion Through HSPG and αvβ1 Integrin, Journal of Cellular Biochemistry, 115, 7, 2014. Crossref

  17. Abdelmagid Samir M., Belcher Joyce Y., Moussa Fouad M., Lababidi Suzanne L., Sondag Gregory R., Novak Kimberly M., Sanyurah Afif S., Frara Nagat A., Razmpour Roshanak, Del Carpio-Cano Fabiola E., Safadi Fayez F., Mutation in Osteoactivin Decreases Bone Formation in Vivo and Osteoblast Differentiation in Vitro, The American Journal of Pathology, 184, 3, 2014. Crossref

  18. Fiorentini Chiara, Bodei Serena, Bedussi Francesca, Fragni Martina, Bonini Sara Anna, Simeone Claudio, Zani Danilo, Berruti Alfredo, Missale Cristina, Memo Maurizio, Spano PierFranco, Sigala Sandra, GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity, Experimental Cell Research, 323, 1, 2014. Crossref

  19. Li Xian, Chen Xiaofeng, Miao Guohou, Liu Hui, Mao Cong, Yuan Guang, Liang Qiming, Shen Xiongjun, Ning Chengyun, Fu Xiaoling, Synthesis of radial mesoporous bioactive glass particles to deliver osteoactivin gene, J. Mater. Chem. B, 2, 40, 2014. Crossref

  20. Nagahara Yuki, Shimazawa Masamitsu, Tanaka Hirotaka, Ono Yoko, Noda Yasuhiro, Ohuchi Kazuki, Tsuruma Kazuhiro, Katsuno Masahisa, Sobue Gen, Hara Hideaki, Glycoprotein nonmetastatic melanoma protein B ameliorates skeletal muscle lesions in a SOD1G93Amouse model of amyotrophic lateral sclerosis, Journal of Neuroscience Research, 93, 10, 2015. Crossref

  21. Tagliaferri Camille, Wittrant Yohann, Davicco Marie-Jeanne, Walrand Stéphane, Coxam Véronique, Muscle and bone, two interconnected tissues, Ageing Research Reviews, 21, 2015. Crossref

  22. Frara Nagat, Abdelmagid Samir M., Sondag Gregory R., Moussa Fouad M., Yingling Vanessa R., Owen Thomas A., Popoff Steven N., Barbe Mary F., Safadi Fayez F., Transgenic Expression of Osteoactivin/gpnmb Enhances Bone Formation In Vivo and Osteoprogenitor Differentiation Ex Vivo, Journal of Cellular Physiology, 231, 1, 2016. Crossref

  23. Sheng Matilda H.-C., Wergedal Jon E., Mohan Subburaman, Amoui Mehran, Baylink David J., Lau K.-H. William, Cicek Muzaffer, Targeted Overexpression of Osteoactivin in Cells of Osteoclastic Lineage Promotes Osteoclastic Resorption and Bone Loss in Mice, PLoS ONE, 7, 4, 2012. Crossref

  24. Sondag Gregory R, Mbimba Thomas S, Moussa Fouad M, Novak Kimberly, Yu Bing, Jaber Fatima A, Abdelmagid Samir M, Geldenhuys Werner J, Safadi Fayez F, Osteoactivin inhibition of osteoclastogenesis is mediated through CD44-ERK signaling, Experimental & Molecular Medicine, 48, 9, 2016. Crossref

  25. Rose April A. N., Annis Matthew G., Dong Zhifeng, Pepin Francois, Hallett Michael, Park Morag, Siegel Peter M., Uversky Vladimir N., ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties, PLoS ONE, 5, 8, 2010. Crossref

  26. Noda Yasuhiro, Tsuruma Kazuhiro, Takata Masafumi, Ishisaka Mitsue, Tanaka Hirotaka, Nakano Yusuke, Nagahara Yuki, Shimazawa Masamitsu, Hara Hideaki, GPNMB Induces BiP Expression by Enhancing Splicing of BiP Pre-mRNA during the Endoplasmic Reticulum Stress Response, Scientific Reports, 7, 1, 2017. Crossref

  27. Metz Rebecca L, Patel Prem S, Hameed Meera, Bryan Margaret, Rameshwar Pranela, Role of human HGFIN/nmbin breast cancer, Breast Cancer Research, 9, 5, 2007. Crossref

  28. Vaklavas Christos, LoBuglio Albert F., Saleh Mansoor, Yelin Michael, Forero Andres, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE), in Antibody-Drug Conjugates and Immunotoxins, 2013. Crossref

  29. Chrystal Paul W., Footz Tim, Hodges Elizabeth D., Jensen Justin A., Walter Michael A., Allison W. Ted, Functional Domains and Evolutionary History of the PMEL and GPNMB Family Proteins, Molecules, 26, 12, 2021. Crossref

  30. Yukata Kiminori, Nikawa Takeshi, Takahashi Mitsuhiko, Yasui Natsuo, Overexpressed osteoactivin reduced osteoclastic callus resorption during distraction osteogenesis in mice, Journal of Pediatric Orthopaedics B, 30, 5, 2021. Crossref

  31. Polito Letizia, Calafato Giulia, Bortolotti Massimo, Chiarelli Olivari Cecilia, Maiello Stefania, Bolognesi Andrea, Antibody Conjugates for Sarcoma Therapy: How Far along Are We?, Biomedicines, 9, 8, 2021. Crossref

  32. Boskey Adele L., Roy Rani, Cell Culture Systems for Studies of Bone and Tooth Mineralization, Chemical Reviews, 108, 11, 2008. Crossref

  33. Ott Patrick A., Hamid Omid, Pavlick Anna C., Kluger Harriet, Kim Kevin B., Boasberg Peter D., Simantov Ronit, Crowley Elizabeth, Green Jennifer A., Hawthorne Thomas, Davis Thomas A., Sznol Mario, Hwu Patrick, Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma, Journal of Clinical Oncology, 32, 32, 2014. Crossref

  34. Rose April A.N., Pepin François, Russo Caterina, Abou Khalil Jad E., Hallett Michael, Siegel Peter M., Osteoactivin Promotes Breast Cancer Metastasis to Bone, Molecular Cancer Research, 5, 10, 2007. Crossref

  35. Rose April A.N., Biondini Marco, Curiel Rafael, Siegel Peter M., Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer, Pharmacology & Therapeutics, 179, 2017. Crossref

  36. Azizova G. I., Hasanova N. A., Dadashova A. R., DYNAMICS OF OSTEOACTIVIN IN PATIENTS WITH OSTEOPOROTIC FRACTURES , Bulletin of Problems Biology and Medicine, 1, 1, 2022. Crossref

  37. Raz-Prag Dorit, Grimes William N., Fariss Robert N., Vijayasarathy Camasamudram, Campos Maria M., Bush Ronald A., Diamond Jeffrey S., Sieving Paul A., Probing potassium channel function in vivo by intracellular delivery of antibodies in a rat model of retinal neurodegeneration, Proceedings of the National Academy of Sciences, 107, 28, 2010. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain